When was NeoImmuneTech founded?

NeoImmuneTech was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is NeoImmuneTech located?

NeoImmuneTech is headquartered in Rockville, United States. It is registered at 2400 Research Blvd., Suite 250, Rockville, MD 20850.

How many employees does NeoImmuneTech have?

As of Aug 31, 2026, the latest employee count at NeoImmuneTech is 37.

Is NeoImmuneTech a funded company?

NeoImmuneTech is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on 2015.

When was the latest funding round of NeoImmuneTech?

NeoImmuneTech's latest funding was a $***** Seed round on 2015, with participation from 1 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.97B in funding in 2026 to date.

Where does NeoImmuneTech rank among its competitors?

NeoImmuneTech ranks 581st amongst 3408 active competitors, of which 1138 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of NeoImmuneTech?

NeoImmuneTech's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

NeoImmuneTech - 2026 Company Profile, Funding & Competitors

NeoImmuneTech is a public company based in Rockville (United States), founded in 2014. It operates as a Developer of immuno-therapeutics for the treatment of immuno-oncology and infectious diseases. NeoImmuneTech has raised an undisclosed amount in funding. The company has 3408 active competitors, including 1138 funded and 796 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of immuno-therapeutics for the treatment of immuno-oncology and infectious diseases. Their proprietary technology is based on a fused T-cell production factor, IL-7-hyFc (Hyleukin). Hyleukin was created by fusing engineered IL-7 to hyFc. The result is a stable, long-acting molecule, which is a safe carrier and can be dosed mucosally or subcutaneously. The product pipeline includes NIT-01, which is a Hyleukin monotherapy, is indicated for Lymphopenias, NIT-02 and NIT-03 are indicated for HPV infections and HPV-related cancers.

Website: www.neoimmunetech.com/en
Email ID: *****@neoimmunetech.com
Phone Number: +1 **********
Registered Address: 2400 Research Blvd., Suite 250, Rockville, MD 20850

Key Metrics

Founded Year

2014

Location

Rockville, United States

Stage

Public

Latest Funding Round

Seed, 2015, $*****

Investors

Shield Investment & 7 more

Ranked

581^st among 3408 active competitors

Employee Count

37 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3110 more

Exit Details

Public

View NeoImmuneTech's full profile

NeoImmuneTech is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
NEOIMMUNETECH, INC. CIN: 20231485639 , United States, Active	May 02, 2023	-	-	-
NeoImmuneTech, Inc CIN: 6912193 , United States, Active	May 31, 2018	-	37 (As on Dec 31, 2022)	-

NeoImmuneTech got listed on Mar 16, 2021.

Click here to take a look at NeoImmuneTech's IPO in detail

NeoImmuneTech has raised funding over 1 round. Its latest funding round was a Seed round on 2015 for $*****. 1 investor participated in its latest round. NeoImmuneTech has 8 institutional investors.

Here is the list of recent funding rounds of NeoImmuneTech:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2015	3985	Seed	9752	4169	2959	6063

Access funding benchmarks and valuations. Sign up today!

View details of NeoImmuneTech's funding rounds and investors

NeoImmuneTech's employee count trend

NeoImmuneTech has 37 employees as of Aug 26. Here is NeoImmuneTech's employee count trend over the years:

Uncover NeoImmuneTech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NeoImmuneTech include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of NeoImmuneTech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
581st	NeoImmuneTech 2014, Rockville (United States), Public	Developer of immuno-therapeutics for the treatment of immuno-oncology and infectious diseases	-	Shield Investment, Partners Investment & 6 others	51/100